Background
Accellta develops, manufactures and markets a range of revolutionary solutions for better affordability and quality of stem cell culturing. Accellta's disruptive technologies are the result of over 15 years of pioneering research and development at the Stem Cell Center in the Rappaport Faculty of Medicine at the Technion- Israel lnstitute of Technology. The company’s ambition is to become a leading provider of human pluripotent stem cell lines and pluripotent stem cell-derived cell lines, reagents and services, for research, drug development, toxicology studies and clinical uses.
Accellta was established in 2012 and is headed by a seasoned team of pioneering scientists and experienced executives; the company operates a top-tier GMP compliant manufacturing facility of over 550 sqm, located Haifa, Israel. The company is currently focused on partnering with biopharma companies, stem cell companies and cell therapy contract manufacturing organizations, for developing innovative solutions for large-scale and cost-effective manufacturing processes for stem cell products.
Aim and objectives
The general aim of Accellta’s market research study was to establish a well thought-out market strategy for Accellta's expanding business goals at the growing field of stem cell-related products.
The objectives were:
• To prepare a complete market study to act as a roadmap for the technological and market advancement of Accellta's technology
• To establish the most profitable future lab-to-market business plan
